GENE ONLINE|News &
Opinion
Blog

Can Regulations Measure up to the Progress of Precision Medicine in Taiwan? – An Interview With Dr. Johnsee Lee

by Joy Lin
Share To

Precision medicine is the opposite of the conventional one-size-fits-all medical approach. Also called personalized medicine, the field takes into account an individual’s genes, lifestyle, and environment before giving them custom-made treatments.  

Molecular diagnostics, which includes genetic testing, plays an indispensable role in precision medicine, displaying a wide variety of uses ranging from detecting diseases to assessing health risks for individuals. 

Precision medicine is gaining traction as healthcare providers acknowledge that every patient tends to respond more favorably to treatments tailored to their specific needs.

GeneOnline recently had the pleasure to interview Dr. Johnsee Lee for his insights on the field of precision medicine and its relevance in Taiwan. Dr. Lee is Chairman of the Taiwan Precision Medical and Molecular Diagnostics Association (PMMD). He is also President and CEO of Quark Biosciences, a diagnostics and precision medicine company.

Related Article: Evolution of Taiwan’s Biotechnology Industry: Policies, Hotspots, and Market Movements

 

From Diagnostics Platforms to Testing Services 

The molecular diagnostics market is divided into three major components: upstream, midstream, and downstream. The upstream sector involves the development of diagnostic platforms, while midstream and downstream sectors focus on detection reagents and testing services, respectively.

International heavyweights such as Illumina and Thermo Fisher dominate the upstream sector. These companies possess well-established core technologies for genome sequencing as well as the development and manufacture of diagnostic instruments.

For midstream, it is vital that detection reagents can accurately verify biomarkers. They can only be developed with the help of vast quantities of biological information and clinical data. 

Finally, we have downstream testing services. While we require service providers to be well-trained in bioinformatics, there isn’t much room for innovation. Still, this is where most Taiwanese companies in the field reside.

In addition to providing these services, Taiwan’s small and medium-sized enterprises and biomedical professionals could invest more actively in the R&D of midstream testing reagents and kits.

Related Article: How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen

 

Molecular Diagnosis, a Multipurpose Tool 

We can’t deny that genetic testing has upended our views on how patients receive treatment. In the past, medical practices tended towards “one size fits all” or standardized interventions. Now, we can look at a patient’s genetics to get a comprehensive profile of their disease before designing a treatment plan for them. Truly, diagnosis lies at the heart of personalized medicine. 

Molecular testing does not end with selecting the right drugs for individuals; it can also be used to assess health risks. For example, genetic screening can detect hereditary disease or early signs of cancer, so timely interventions can take place to prevent disease progression.

From a post-treatment perspective, we could use molecular diagnostics to track diseases in real-time. In the case of cancer, a genetic analysis of liquid biopsy samples taken from the patient can yield valuable information on the changes happening in their tumors or predict whether a cancer is likely to recur.

 

A Window of Opportunity for Precision Medicine in Taiwan?

Taiwan is not the fastest when it comes to accepting emerging medical technologies such as molecular testing. Current regulations limit the rollout of services, which must undergo a lengthy review and show clinical proof of concept to be eligible for reimbursement schemes under the health insurance system. Furthermore, there aren’t enough collaborative opportunities between the diagnostic developers and medical practitioners who perform testing services.  

The emphasis on personalized medicine is growing, and so too is the market for molecular testing. According to a MarketsandMarkets estimate, the global molecular diagnostic market will reach $31.8 billion by 2026. To secure a slice of that pie, Taiwan will need to make its laws and regulations more open and responsive.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Micronbrane Medical Aspires to Further Clinical Collaboration Following the Successful Series A Funding
2022-12-01
CK Life Sciences and CK Hutchison Invest in Taiwanese Liquid Biopsy Candidate
2022-07-26
Reinvigorating the Asian Biomedical Ecosystem With BIO Asia-Taiwan 2022
2022-07-26
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!